Pharming Group Overview
- Year Founded
-
1988
- Status
-
Public
- Employees
-
409
- Stock Symbol
-
PHARM
- Investments
-
10
- Share Price
-
$1.22
- (As of Thursday Closing)
Pharming Group General Information
Description
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
Contact Information
Website
www.pharming.comCorporate Office
- Vondellaan 47
- 2332 AA Leiden
- Netherlands
Corporate Office
- Vondellaan 47
- 2332 AA Leiden
- Netherlands
Pharming Group Stock Performance
As of 19-Nov-2026, Pharming Group’s stock price is $1.22. Its current market cap is $866M with 708M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.22 | $1.23 | $0.92 - $2.18 | $866M | 708M | 8.44M | $0.04 |
Pharming Group Financials Summary
As of 30-Sep-2026, Pharming Group has a trailing 12-month revenue of $387M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 667,423 | 1,131,665 | 611,307 | 716,953 |
| Revenue | 386,717 | 376,134 | 297,200 | 245,316 |
| EBITDA | 46,281 | 33,529 | 7,844 | 6,214 |
| Net Income | 24,153 | 2,851 | (11,841) | (10,548) |
| Total Assets | 496,637 | 499,963 | 399,985 | 462,854 |
| Total Debt | 114,513 | 115,775 | 112,313 | 171,545 |
Pharming Group Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Pharming Group Comparisons
Industry
Financing
Details
Pharming Group Competitors (44)
One of Pharming Group’s 44 competitors is uniQure, a Formerly VC-backed company based in Amsterdam, Netherlands.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| uniQure | Formerly VC-backed | Amsterdam, Netherlands | ||||
| Eurofins Advinus | Corporate Backed or Acquired | Bangalore, India | ||||
| Biocon | Formerly PE-Backed | Bengaluru, India | ||||
| Evotec | Formerly PE-Backed | Hamburg, Germany | ||||
| Takeda Pharmaceutical | Corporation | Tokyo, Japan |
Pharming Group Patents
Pharming Group Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026171834-A1 | Pi3k delta inhibitors for use in the treatment of immune dysregulation in common variable immunodeficiency | Pending | 14-Feb-2025 | ||
| AU-2024326448-A1 | Quinones for use in the treatment of red blood cell enzymopathies | Pending | 21-Aug-2023 | ||
| AU-2024329068-A1 | Quinones for use in the treatment of red blood cell enzymopathies | Pending | 21-Aug-2023 | ||
| EP-4766345-A1 | Quinones for use in the treatment of red blood cell enzymopathies | Pending | 21-Aug-2023 | ||
| EP-4766346-A1 | Quinones for use in the treatment of red blood cell enzymopathies | Pending | 21-Aug-2023 | C07D235/02 |
Pharming Group Signals
Pharming Group Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Pharming Group Investments & Acquisitions (10)
Pharming Group’s most recent deal was a Secondary Transaction - Private with Abliva for . The deal was made on 18-Jun-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Abliva | 18-Jun-2025 | Secondary Transaction - Private | Drug Discovery | ||
| Abliva | 14-Feb-2025 | Merger/Acquisition | Drug Discovery | ||
| Pharming Group (EU Commercial Rights) | 01-Jan-2020 | Corporate Asset Purchase | Buildings and Property | ||
| Novartis (Leniolisib) | 13-Aug-2019 | Corporate Asset Purchase | Buildings and Property | ||
| BioConnection | 09-Apr-2019 | Corporate | BPO/Outsource Services |
Pharming Group ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
27.74 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Pharming Group Exits (1)
Pharming Group’s most recent exit was on 23-Mar-2006 from Dnage. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Dnage | 23-Mar-2006 | Completed |
|
Pharming Group Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Abliva | Lund, Sweden | 2000 |
Pharming Group FAQs
-
When was Pharming Group founded?
Pharming Group was founded in 1988.
-
Where is Pharming Group headquartered?
Pharming Group is headquartered in Leiden, Netherlands.
-
What is the size of Pharming Group?
Pharming Group has 409 total employees.
-
What industry is Pharming Group in?
Pharming Group’s primary industry is Pharmaceuticals.
-
Is Pharming Group a private or public company?
Pharming Group is a Public company.
-
What is Pharming Group’s stock symbol?
The ticker symbol for Pharming Group is PHARM.
-
What is the current stock price of Pharming Group?
As of 19-Nov-2026 the stock price of Pharming Group is $1.22.
-
What is the current market cap of Pharming Group?
The current market capitalization of Pharming Group is $866M.
-
What is Pharming Group’s current revenue?
The trailing twelve month revenue for Pharming Group is $387M.
-
Who are Pharming Group’s competitors?
uniQure, Eurofins Advinus, Biocon, Evotec, and Takeda Pharmaceutical are some of the 44 competitors of Pharming Group.
-
What is Pharming Group’s annual earnings per share (EPS)?
Pharming Group’s EPS for 12 months was $0.04.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process